Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GRM3 antisense RNA 1 (GRM3-AS1) is a poorly characterized long non-coding RNA (lncRNA) gene, transcribed antisense to the GRM3 gene (Glutamate metabotropic receptor 3) on chromosome 7[2]. Functionally, its role is not well established, but single nucleotide polymorphisms affecting or located within the GRM3-AS1/GRM3 locus have been statistically associated with increased risk for psychiatric and neurodevelopmental disorders, including schizophrenia and autism spectrum disorder[2]. There is no evidence that this lncRNA encodes a receptor, enzyme, transporter, or other classic protein target suitable for direct pharmacological modulation. GRM3-AS1 may be relevant for gene regulation or as a genetic biomarker in genome-wide association studies, but no direct biological function, druggability, or validated disease mechanism has been established. This entry does not represent a classical "target" such as a receptor, enzyme, transporter, or transcription factor. Instead, it is an antisense non-coding RNA with speculative regulatory functions. It should not be conflated with GRM3, which encodes the metabotropic glutamate receptor 3—a validated therapeutic target implicated in brain disorders[1][3][4][5]. If you meant to refer to GRM3 (the protein-coding gene) or its protein product, see entries under "metabotropic glutamate receptor 3" or "GRM3."
Not applicable for drugs; no known targeted molecular mechanism
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GRM3 antisense RNA 1 (GRM3-AS1).